Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. is a biopharmaceutical company focused on researching, developing, and commercializing immunotherapies for cancer treatment. With a diverse portfolio of biosimilars and novel immuno-oncology assets, Coherus aims to improve patient outcomes and expand treatment options.
Company Overview
Coherus Oncology is a biopharmaceutical innovator specializing in immunotherapies and biosimilars for cancer, offering a diversified portfolio with LOQTORZI and UDENYCA, and a robust pipeline targeting unmet needs in oncology, making it a compelling investment in the rapidly evolving cancer treatment landscape.
Investment Thesis
Coherus Oncology presents a compelling investment opportunity due to its diversified portfolio of biosimilars and novel immunotherapies. The company's focus on oncology, highlighted by the launch of LOQTORZI, a next-generation PD-1 inhibitor, positions it for significant growth in the expanding cancer treatment market. With a market capitalization of $0.26 billion and a P/E ratio of 1.61, Coherus exhibits attractive valuation metrics. The company's high profit margin of 185.4% indicates strong operational efficiency. Key catalysts include the continued commercialization of LOQTORZI and the advancement of its pipeline assets, such as Casdozokitug and CHS-114. Successful execution of these initiatives could drive substantial revenue growth and increase shareholder value within the next 2-3 years.
Key Highlights
- Market capitalization of $0.26 billion indicates the current market valuation of Coherus Oncology.
- P/E ratio of 1.61 suggests the stock may be undervalued compared to its earnings.
- Profit margin of 185.4% demonstrates strong profitability and efficient cost management.
- Gross margin of 47.8% reflects the company's ability to generate revenue after accounting for the cost of goods sold.
- Beta of 1.02 indicates the stock's volatility is similar to the overall market.
Competitors
Strengths
- Diversified product portfolio with both biosimilars and novel immunotherapies.
- Strong profit margin of 185.4%.
- Established partnerships with leading biotechnology companies.
- Experienced management team with a track record of successful biosimilar development.
Weaknesses
- Reliance on regulatory approvals for pipeline assets.
- Competition from established pharmaceutical companies and other biotechnology firms.
- Potential for biosimilar price erosion.
- Relatively small market capitalization compared to industry giants.
Catalysts
- Upcoming: Continued commercial rollout and market penetration of LOQTORZI in approved indications.
- Upcoming: Clinical trial results for Casdozokitug in various cancer types.
- Upcoming: Potential regulatory approvals for new biosimilars in the pipeline.
- Ongoing: Expansion of strategic collaborations and licensing agreements.
- Ongoing: Increasing adoption of biosimilars in the healthcare market.
Risks
- Potential: Unfavorable clinical trial results for pipeline assets.
- Potential: Regulatory delays or rejections for new products.
- Ongoing: Competition from established pharmaceutical companies and other biotechnology firms.
- Ongoing: Patent challenges from competitors.
- Potential: Economic downturn impacting healthcare spending.
Growth Opportunities
- Continued Commercialization of LOQTORZI: LOQTORZI, a novel next-generation PD-1 inhibitor, represents a significant growth opportunity for Coherus. The PD-1/PD-L1 inhibitor market is projected to reach $40 billion by 2028. Successful commercialization and expansion into new indications could drive substantial revenue growth over the next 3-5 years. Coherus's competitive advantage lies in its innovative formulation and potential for improved efficacy compared to existing PD-1 inhibitors.
- Advancement of Casdozokitug: Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27, holds promise as a novel cancer therapy. The market for IL-27 targeted therapies is nascent but expected to grow rapidly as clinical data emerges. Positive clinical trial results and subsequent regulatory approval could create a significant revenue stream for Coherus within the next 5 years. The company's expertise in antibody development provides a competitive edge.
- Expansion of Biosimilar Portfolio: Coherus has a strong track record in developing and commercializing biosimilars, including UDENYCA, YUSIMRY, and CIMERLI. The global biosimilars market is projected to reach $100 billion by 2027. Expanding its biosimilar portfolio to include additional high-value targets can drive sustainable growth and diversify revenue streams over the next 2-3 years. Coherus's established manufacturing and regulatory capabilities provide a competitive advantage.
- Development of CHS-114 and CHS-1000: CHS-114, targeting Treg cells in the tumor microenvironment, and CHS-1000, an Anti-ILT4 monoclonal antibody, represent promising immuno-oncology assets. The market for therapies targeting the tumor microenvironment is growing rapidly. Successful clinical development and commercialization of these assets could generate significant revenue within the next 5-7 years. Coherus's focus on innovative immuno-oncology targets differentiates it from competitors.
- Strategic Collaborations and Licensing Agreements: Coherus has established strategic collaborations and licensing agreements with companies like Junshi Biosciences, Surface and Adimab LLC, Bioeq AG, and Genentech, Inc. These partnerships provide access to novel technologies and expand the company's research and commercialization capabilities. Leveraging these collaborations can accelerate pipeline development and drive long-term growth. The value of strategic partnerships in the biotechnology industry is expected to increase as companies seek to share risks and access specialized expertise.
Opportunities
- Expansion into new indications for existing products.
- Acquisition of additional pipeline assets.
- Strategic partnerships to expand global reach.
- Increased adoption of biosimilars to reduce healthcare costs.
Threats
- Unfavorable clinical trial results.
- Regulatory delays or rejections.
- Patent challenges from competitors.
- Economic downturn impacting healthcare spending.
Competitive Advantages
- Strong intellectual property portfolio protecting its biosimilars and novel therapies.
- Established manufacturing and regulatory expertise in biosimilar development.
- Strategic collaborations with leading biotechnology companies.
- Diversified product portfolio across oncology and inflammatory diseases.
- Focus on innovative immuno-oncology targets.
About
Coherus Oncology, Inc., founded in 2010 and headquartered in Redwood City, California, is a biopharmaceutical company dedicated to researching, developing, and commercializing innovative immunotherapies to combat cancer. Originally named Coherus BioSciences, the company rebranded in May 2025 to reflect its sharpened focus on oncology. Coherus's portfolio includes UDENYCA, a biosimilar to Neulasta used to reduce the risk of infection in cancer patients undergoing chemotherapy, and LOQTORZI, a novel next-generation programmed death receptor-1 (PD-1) inhibitor. The company is also developing Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. Further pipeline assets include CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME), and CHS-1000, an Anti-ILT4 monoclonal antibody for solid tumors. Beyond its core oncology pipeline, Coherus markets YUSIMRY, a biosimilar to Humira, addressing inflammatory diseases, and CIMERLI, a Lucentis biosimilar for treating various retinal conditions. Coherus has established strategic collaborations with companies like Junshi Biosciences for toripalimab, Surface and Adimab LLC, Bioeq AG, Genentech, Inc., Surface and Vaccinex, Inc., Novartis Institutes for Biomedical Research, Inc., and GlaxoSmithKline Intellectual Property No. 4 Limited, expanding its research and commercialization capabilities.
What They Do
- Researches and develops immunotherapies for cancer treatment.
- Commercializes biosimilars to reduce healthcare costs.
- Develops novel oncology assets targeting unmet medical needs.
- Offers UDENYCA, a biosimilar to Neulasta, to prevent infections in chemotherapy patients.
- Markets LOQTORZI, a next-generation PD-1 inhibitor, for cancer treatment.
- Develops Casdozokitug, an investigational antibody targeting interleukin 27.
- Provides YUSIMRY, a biosimilar to Humira, for inflammatory diseases.
- Offers CIMERLI, a Lucentis biosimilar, for retinal conditions.
Business Model
- Develops and commercializes biosimilars of established biologic drugs.
- Creates and out-licenses novel immunotherapies for cancer treatment.
- Generates revenue through product sales and licensing agreements.
- Collaborates with other companies to expand its research and development capabilities.
Industry Context
Coherus Oncology operates within the biotechnology sector, which is characterized by rapid innovation and intense competition. The oncology market is experiencing substantial growth, driven by an aging population and advancements in cancer diagnostics and treatments. Key market trends include the development of personalized immunotherapies and the increasing adoption of biosimilars to reduce healthcare costs. Coherus competes with established pharmaceutical companies and other biotechnology firms, including AVTX, CCCC, CDXS, IMDX, and IVVD, striving to differentiate itself through its novel immuno-oncology assets and biosimilar portfolio.
Key Customers
- Cancer patients undergoing chemotherapy.
- Patients with inflammatory diseases like rheumatoid arthritis.
- Patients with retinal conditions such as macular degeneration.
- Hospitals and oncology clinics.
- Healthcare providers prescribing medications.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $12M | -$36M | $-0.31 |
| Q2 2025 | $10M | $298M | $2.57 |
| Q1 2025 | $8M | -$57M | $-0.49 |
| Q4 2024 | $54M | -$51M | $-0.44 |
Source: Company filings
Chart & Info
Price Chart
Coherus Oncology, Inc. (CHRS) stock price: $1.36 (+0.00, +0.00%)
Latest News
-
12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga · Feb 13, 2026
-
Why Applied Materials Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
benzinga · Feb 13, 2026
-
Top Midday Gainers
MT Newswires · Jan 23, 2026
-
12 Health Care Stocks Moving In Friday's Intraday Session
benzinga · Jan 23, 2026
Technical Analysis
Rationale
AI-generated technical analysis for CHRS including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Coherus Oncology, Inc. (CHRS) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for CHRS.
Make a Prediction
Set your price target for Coherus Oncology, Inc. (CHRS), choose a timeframe, and track your prediction accuracy.
Current price: $1.36
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CHRS.
Price Targets
Median: $6.00 (+342.6% from current price)
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 4/100
Revenue grew only 3.8% YoY, suggesting the company is in a slower growth phase.
-
Gross Margin 8/100
Gross margin at 47.8% indicates good unit economics and healthy profitability per sale.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 8/100
Strong cash reserves of $126M provide a solid financial cushion for growth investments and market downturns.
-
R&D Intensity 10/100
Investing 35.0% of revenue in R&D signals heavy commitment to innovation and future product pipeline.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 7/100
Active trading at 3.62% daily turnover suggests elevated interest, which can increase volatility.
-
Price Momentum 3/100
Weak momentum with few bullish signals. The stock may be in a downtrend or consolidation phase.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates CHRS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
12 Health Care Stocks Moving In Friday's Pre-Market Session
Why Applied Materials Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Top Midday Gainers
12 Health Care Stocks Moving In Friday's Intraday Session
Frequently Asked Questions
What does Coherus Oncology, Inc. do?
Coherus Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing both biosimilars and novel immunotherapies, primarily targeting cancer treatment. The company's portfolio includes UDENYCA, a biosimilar to Neulasta, and LOQTORZI, a next-generation PD-1 inhibitor. Coherus aims to provide cost-effective treatment options through biosimilars while also innovating in the immuno-oncology space with novel therapies like Casdozokitug and CHS-114, addressing unmet medical needs and improving patient outcomes in the oncology market.
Is CHRS stock a good buy?
CHRS stock presents a mixed investment profile. The company's high profit margin of 185.4% and a low P/E ratio of 1.61 suggest potential undervaluation. The successful commercialization of LOQTORZI and advancement of its pipeline could drive future growth. However, risks include regulatory hurdles, competition, and potential patent challenges. Investors should weigh the growth potential against these risks and consider their own risk tolerance before investing. A thorough analysis of clinical trial data and market dynamics is recommended.
What are the main risks for CHRS?
The main risks for Coherus Oncology include regulatory risks associated with drug approvals, competition from established pharmaceutical companies and biosimilar manufacturers, and potential patent challenges. Clinical trial failures for pipeline assets could significantly impact the company's valuation. Economic downturns could also affect healthcare spending and demand for the company's products. Furthermore, the company's reliance on a few key products exposes it to concentration risk. Effective risk management and diversification strategies are crucial for Coherus to mitigate these challenges.
Is CHRS a good stock to buy?
Whether CHRS is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the CHRS MoonshotScore?
The MoonshotScore for CHRS is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is CHRS data updated?
CHRS stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to CHRS is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for CHRS?
Growth catalysts for Coherus Oncology, Inc. (CHRS) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Coherus Oncology, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are CHRS's main competitors?
Coherus Oncology, Inc. (CHRS) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether CHRS has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about CHRS?
Wall Street analyst coverage for CHRS includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is CHRS's market cap?
Market capitalization (market cap) for CHRS is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows CHRS's current market cap alongside enterprise value and other valuation metrics.
How has CHRS stock performed recently?
CHRS's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing CHRS's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in CHRS?
Key risk categories for CHRS include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures CHRS's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling CHRS?
Insider trading activity for CHRS tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is CHRS a good stock for beginners?
Coherus Oncology, Inc. (CHRS) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is CHRS for first-time investors?
Every stock carries risk, including Coherus Oncology, Inc. (CHRS). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like CHRS.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment decisions should be based on individual risk tolerance and due diligence.